PranaX Licenses Exosome Technology to Commercialize Stem Cell Exosomes PranaX Licenses Exosome Technology to Commercialize Stem Cell Exosomes PR Newswire HOUSTON, March 13, 2025 HOUSTON, March 13, ...

Heart failure (HF) is a global health problem characterized by impaired heart function. Cardiac remodeling and cell death contribute to the development of HF. Although treatments such as digoxin and ...

New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. It’s not your imagination. Whether you’re scanning ...

These exosomes contain a potent molecule, miR-4645-5p, that significantly boosts the healing process. This study delves into the use of exosomes from hypoxic bone marrow mesenchymal stem cells (BMSCs) ...

A new editorial paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "Therapeutically harnessing cancer stem cell-derived exosomes." In this editorial, researcher Yong Teng ...

Lydian Cosmetic Surgery Clinic in Seoul announces its autologous regenerative therapies, including stem cell and exosome ...

There's a lot we don't know, and one thing experts know for certain.

Cellular communication is vital for passing information to neighboring cells. One key messenger in this process is an exosome, a nanosized particle that buds off from a progenitor cell, carrying ...

The license agreement grants PranaX access to a core patent portfolio covering exosome manufacturing, engineering and therapeutic applications through a technology licensing agreement. This agreement ...